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Circulating Total Bilirubin and Future Risk of Hypertension in the
General Population: The Prevention of Renal and Vascular End-Stage
Disease (PREVEND) Prospective Study and a Mendelian
Randomization Approach
Setor K. Kunutsor, MD, PhD; Lyanne M. Kieneker, MSc; Stephen Burgess, PhD; Stephan J.L. Bakker, MD, PhD; Robin P.F. Dullaart,
MD, PhD
Background-—Circulating total bilirubin is known to be inversely and independently associated with future risk of cardiovascular
disease. However, the relationship of circulating total bilirubin with incident hypertension is uncertain. We aimed to assess the
association of total bilirubin with future hypertension risk and supplemented this with a Mendelian randomization approach to
investigate any causal relevance to the association.
Methods and Results-—Plasma total bilirubin levels were measured at baseline in the PREVEND (Prevention of Renal and Vascular
End-Stage Disease) prospective study of 3989 men and women without hypertension. Hazard ratios (95% conﬁdence intervals) of
total bilirubin with incident hypertension were assessed. New-onset hypertension was recorded in 1206 participants during a
median follow-up of 10.7 years. Baseline total bilirubin was approximately log-linearly associated with hypertension risk. Age- and
sex-adjusted hazard ratio for hypertension per 1-SD increase in loge total bilirubin was 0.86 (0.81–0.92; P<0.001), which was
attenuated to 0.94 (0.88–0.99; P=0.040) after further adjustment for established risk factors and other potential confounders. The
association was marginally signiﬁcant on further adjustment for high-sensitivity C-reactive protein (0.94; 0.88–1.00; P=0.067). A
genetic variant at the UGT1A1*28 locus consistently shown to be strongly associated with circulating bilirubin levels—rs6742078
—was not signiﬁcantly associated with blood pressure or hypertension (P>0.05 for all), arguing against a strong causal association
of circulating bilirubin with blood pressure.
Conclusions-—The weak and inverse association of circulating total bilirubin with future hypertension risk may be driven by biases
such as unmeasured confounding and/or reverse causation. Further evaluation is warranted. ( J Am Heart Assoc. 2017;6:
e006503. DOI: 10.1161/JAHA.117.006503.)
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C irculating total bilirubin has been consistently shown tobe inversely and independently associated with cardio-
vascular disease (CVD) risk.1 Plausible mechanisms by which
higher total bilirubin contributes to reduced CVD risk have
been attributed to its antioxidant,2,3 anti-inﬂammatory,4 and
antiatherogenic properties.5 Given the graded, inverse, and
independent association between total bilirubin levels and
CVD risk, there have been suggestions of a causal relation-
ship. However, ﬁndings from 2 Mendelian randomization (MR)
studies have not provided strong evidence for a causal
association between total bilirubin levels and coronary heart
disease risk.6,7 Hypertension, which is a leading risk factor
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for the global burden of disease, is a key intermediate
modiﬁable phenotype for CVD development8 and is included
in the standard cardiovascular risk assessment panel.9 Major
risk factors for hypertension include physical inactivity,
obesity, and excess alcohol intake.10,11 Given the close link
between CVD and hypertension and the fact that they share
common antecedent risk factors, there is emerging evidence
that total bilirubin might also be linked to the development of
hypertension. Indeed, a number of studies conducted in
animal models suggest that bilirubin might reduce blood
pressure through decreases in vascular oxidative stress.12,13
A number of epidemiological observational studies have also
suggested inverse associations. However, uncertainties
remain about the nature and magnitude of the prospective
association between total bilirubin and high blood pressure or
hypertension, given that the majority of these limited earlier
reports were based on cross-sectional designs,14 were
insufﬁciently powerful to address aspects of the associa-
tion,15,16 were based on younger populations,17 or were
conducted in populations with pre-existing disease.15 In a
recent analysis of data from the National Health and Nutrition
Examination Surveys 1999–2012, which was based on a
random sample of over 31 000 individuals, the researchers
reported an inverse association between serum bilirubin and
hypertension.14 Though the analysis was robust, the ﬁndings
were limited by the cross-sectional study design. With the
ongoing debate on the potential value of total bilirubin levels
in prevention and control of hypertension as well as coronary
heart disease,14,18–20 it will be clinically useful if circulating
total bilirubin is shown to contribute to the development of
future hypertension. In this context, our aim was to
characterize and quantify more reliably the nature and
magnitude of the prospective association between total
bilirubin and the risk of future hypertension in the general
population; by utilizing a large population-based sample of
3989 participants from the well-established PREVEND
(Prevention of Renal and Vascular End-Stage Disease) study,
who were free of hypertension and pre-existing apparent
disease at baseline. Furthermore, we evaluated whether there
might be a causal relation between total bilirubin and the
development of hypertension, by querying the associations of
systolic blood pressure (SBP), diastolic blood pressure (DBP),
and hypertension with a common single-nucleotide variant
(SNV) found at the UGT1A1*28 locus—rs6742078—using
published genome-wide association studies. Because of the
strong link between the rs6742078 SNV and bilirubin,21,22
the use of this variant to assess the causal association
between bilirubin and blood pressure is an informative
application of the MR approach.
Materials and Methods
This report was conducted according to STROBE (Strengthen-
ing the Reporting of Observational Studies in Epidemiology)
guidelines for reporting observational studies in epidemiology
(Table S1).23
Study Population
This study was part of the ongoing PREVEND study, a large-
scale, observational, general population cohort study based
in The Netherlands and which began in 1997. The PREVEND
study was designed to investigate the predictive value of
urinary albumin excretion and its relationship to renal and
CVD progression. Details of the study design and recruit-
ment have been described in previous reports.24,25 Brieﬂy,
8592 inhabitants aged 28 to 75 years were recruited from
the city of Groningen in The Netherlands. Baseline measure-
ments were performed between 1997 and 1998. For this
analysis, we used data of participants who did not have
CVD, hypertension, renal disease, or malignancy at baseline,
which left a cohort of 3989 participants with nonmissing
information on total bilirubin levels, relevant covariates, and
incident hypertension. The PREVEND study was approved by
the local medical ethics committee in accord with the
Declaration of Helsinki. All participants provided written
informed consent.
For the genetic association study, we utilized publicly
available data from the International Consortium of Blood
Pressure and the BPExome consortia, which have both been
described in detail elsewhere.26,27 Brieﬂy, the International
Consortium of Blood Pressure involves a meta-analysis of
Clinical Perspective
What Is New?
• In a population-based, prospective study of white men and
women without a history of hypertension and pre-existing
apparent disease at baseline, increasing levels of circulating
total bilirubin was associated with a reduced risk of future
hypertension, which was consistent with a dose-response
relationship.
• Findings from a Mendelian randomization approach pro-
vided weak evidence against a strong causal association of
circulating bilirubin with blood pressure.
What Are the Clinical Implications?
• Lifestyle interventions and pharmacological agents that
cause safe elevations in circulating levels of bilirubin may
represent a novel therapeutic target for the prevention of
hypertension and, consequently, cardiovascular disease;
however, further evaluation is needed.
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genome-wide association studies data evaluating the associ-
ations between 2.5 million genotyped or imputed single-
nucleotide polymorphisms and SBP and DBP in 69 395
individuals of European ancestry from 29 studies. The
BPExome consortium is also a meta-analysis of genome-wide
association studies data from 51 studies comprising 192 763
individuals, which assessed the associations of 242 296
SNVs with DBP, SBP, pulse pressure, and hypertension. The
rs6742078 SNV was a suitable instrumental variable for the
present analyses, given its robust speciﬁcity for serum total
bilirubin levels (explaining up to 45% of the variation in
circulating serum bilirubin levels22) and its use in previous
studies to assess the causal relevance of total bilirubin to
several disease outcomes.6,7,21
Risk-Factor Assessment
Participants completed 2 outpatient visits to assess baseline
data on demographics, anthropometric measurements, car-
diovascular and renal history, and use of medication.
Furthermore, information on medication use was comple-
mented with data from all community pharmacies in the city
of Groningen, which covers complete information on drug use
in 95% of PREVEND participants. Blood pressure values were
recorded as the mean of the last 2 readings of both visits,
because this provides the values after stabilization of blood
pressure. Blood pressure was measured at the right arm, in
the supine position, every minute for 10 and 8 minutes,
respectively, with an automatic device (Dinamap XL Model
9300; Johnson-Johnson Medical, Tampa, FL). After an over-
night fast and 15 minutes of rest, venous blood was obtained
from participants. Plasma samples were prepared by cen-
trifugation at 4°C. Plasma total bilirubin was measured by a
colorimetric assay (2,4-dicholoraniline reaction; Merck MEGA,
Darmstadt, Germany), with the detection limit being
1.0 mmol/L. Interassay coefﬁcients of variation were 3.8%
and 2.9% in the lower normal and higher normal range,
respectively. Glucose, total cholesterol, fasting insulin, and
hsCRP (high-sensitivity C-reactive protein) were measured
using standard laboratory protocols, which have been previ-
ously described.28–30 Urinary albumin excretion was esti-
mated as the mean of two 24-hour urine collections, and the
concentration was determined by nephelometry (BNII; Dade
Behring Diagnostics, Marburg, Germany). Estimated glomeru-
lar ﬁltration rate was calculated using the Chronic Kidney
Disease Epidemiology Collaboration combined creatinine-
cystatin C equation.31
End Point Ascertainment
The primary outcome for this study was ﬁrst-onset hyper-
tension. Incident hypertension was deﬁned as SBP of
≥140 mm Hg, a DBP of ≥90 mm Hg, or the use of
antihypertensive medication, in accord with recommenda-
tions from the Seventh Joint National Committee on Preven-
tion, Detection, Evaluation, and Treatment of High Blood
Pressure.32
Statistical Analysis
Skewed variables (eg, total bilirubin and hsCRP) were natural
log-transformed to achieve approximately normal distribu-
tions. Descriptive analyses were preformed to summarize
baseline characteristics of participants. We assessed cross-
sectional associations of total bilirubin levels with risk
markers for hypertension by calculating partial correlation
coefﬁcients adjusted for age and sex. Cox proportional
hazards models were used to assess the association
between total bilirubin and incident hypertension risk after
conﬁrmation of no major departure from the proportionality
of hazards assumptions using Schoenfeld residuals.33 To
characterize the shape of the association between total
bilirubin and hypertension risk, hazard ratios estimated
within quartiles of baseline total bilirubin levels relative to
the bottom quartile were plotted against mean loge total
bilirubin levels in each quartile using ﬂoating absolute
risks,34 details of which have been described previously.35
Subsidiary analyses involved ﬁtting multivariate-adjusted
fractional polynomial models. Total bilirubin was modeled
as both continuous (per 1-SD higher loge total bilirubin
levels) and categorical (quartiles deﬁned according to the
baseline distribution of total bilirubin level) variables. The SD
of baseline loge total bilirubin level was 0.43 (equivalent to
1.5-fold higher circulating total bilirubin level, as e0.43=1.54).
Hazard ratios were progressively adjusted for (1) age and
sex; (2) other established risk factors for hypertension
(smoking status, history of diabetes mellitus, SBP, total
cholesterol, body mass index, parental history of hyperten-
sion, alcohol consumption, and estimated glomerular ﬁltra-
tion rate); (3) other potential confounders (urinary albumin
excretion and homeostasis model assessment of insulin
resistance); and (4) hsCRP. Selection of these confounders
were based on their previously established role as risk
factors for hypertension, evidence from previous research, or
their potential as confounders based on known associations
with the outcome of hypertension and observed associations
with plasma total bilirubin using the available data. We used
formal tests of interaction tests to assess statistical evidence
of effect modiﬁcation by individual characteristics, such as
age, sex, and other risk markers for hypertension. To avoid
potential bias attributed to reverse causation, we carried out
sensitivity analyses that excluded participants with a history
of diabetes mellitus at baseline, the ﬁrst 2 years of follow-up,
or participants on regular statin medication, or participants
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with potential Gilbert’s syndrome.1 We also utilized the use
of complex survey design analyses,36 taking into account
that the PREVEND cohort is oversampled for subjects with
higher albuminuria levels, which enables the results to be
extrapolated to the general population. All statistical analy-
ses were conducted using Stata software (version 14;
StataCorp LP, College Station, TX). The associations of
rs6742078 were queried with SBP and DBP using data from
the International Consortium of Blood Pressure and with SBP,
DBP, and hypertension using data from the BPExome
consortium.37
Results
Baseline Characteristics and Correlates of Total
Bilirubin
Mean age of participants at study entry was 45 (SD, 11)
years and 55% were women. Mean (SD) of loge total
bilirubin level was 1.94 (0.43) lmol/L. Figure S1 shows a
histogram representing the frequency distribution of total
bilirubin levels in the study sample. Baseline descriptive
characteristics of the participants are shown in Table 1.
Except for parental history of hypertension, there were
Table 1. Baseline Participant Characteristics Overall and According to the Development of Incident Hypertension
Overall (N=3989)
Mean (SD) or Median
(IQR) or n (%)
Without Incident
Hypertension (N=2783)
Mean (SD) or Median
(IQR) or n (%)
With Incident
Hypertension (N=1206)
Mean (SD) or Median
(IQR) or n (%) P Value*
Total bilirubin, lmol/L† 7 (5–9) 7 (5–9) 7 (5–9) <0.001
Questionnaire
Males‡ 1790 (44.9) 1188 (42.7) 602 (49.9) <0.001
Age at survey, y§ 45 (11) 43 (10) 50 (10) <0.0001
History of diabetes mellitus‡ 19 (0.5) 9 (0.3) 10 (0.8) 0.033
Smoking‡
Current 1365 (34.2) 942 (33.9) 423 (35.1)
Former 1351 (33.9) 914 (32.8) 437 (36.2) 0.012
Never 1273 (31.9) 927 (33.3) 346 (28.7)
Alcohol consumers‡ 3121 (78.2) 2217 (79.7) 904 (75.0) 0.001
Parental history of
hypertension‡
1185 (29.7) 807 (29.0) 378 (31.3) 0.136
Physical measurements
BMI, kg/m2§ 25 (4) 25 (3) 26 (4) <0.0001
WHR§ 0.86 (0.09) 0.84 (0.08) 0.88 (0.09) <0.0001
SBP, mm Hg§ 119 (11) 116 (10) 125 (10) <0.0001
DBP, mm Hg§ 70 (7) 68 (7) 74 (7) <0.0001
Lipid, metabolic, inflammatory, and renal markers
Total cholesterol, mmol/L§ 5.48 (1.11) 5.35 (1.07) 5.77 (1.14) <0.0001
Glucose, mmol/L§ 4.63 (0.87) 4.55 (0.71) 4.82 (1.13) <0.0001
Fasting insulin, units/mL† 7.1 (5.1–10.2) 6.8 (4.9–9.6) 7.8 (5.5–11.6) <0.0001
HOMA-IR† 1.43 (0.99–2.12) 1.36 (0.96–1.94) 1.65 (1.10–2.50) <0.0001
hsCRP, mg/L† 0.95 (0.43–2.30) 0.85 (0.38–2.00) 1.29 (0.58–2.87) <0.0001
eGFR, mL/min per 1.73 m2§ 92.3 (14.0) 93.7 (13.5) 88.9 (14.3) <0.0001
UAE, mg/24 h† 8.04 (5.86–12.45) 7.61 (5.72–11.48) 9.18 (6.38–15.55) <0.0001
BMI indicates body mass index; DBP, diastolic blood pressure; eGFR, estimated glomerular ﬁltration rate (as calculated using the Chronic Kidney Disease Epidemiology Collaboration
combined creatinine-cystatin C equation); HDL-C, high-density lipoprotein cholesterol; HOMA-IR, homeostasis model assessment of insulin resistance; hsCRP, high-sensitivity C-reactive
protein; IQR, interquartile range; SBP, systolic blood pressure; UAE, urinary albumin excretion; WHR, waist-to-hip ratio.
*Utilized a 2-sample t tests for a difference in means for continuous variables and a chi-square test for categorical variables.
†
Reported as median (IQR).
‡
Reported as n (%).
§
Reported as mean (SD).
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signiﬁcant differences in baseline clinically relevant sub-
groups and levels of risk markers between participants who
did and did not develop hypertension during follow-up. There
were weak and inverse correlations of loge total bilirubin
levels with physical measures (body mass index, waist-to-hip
ratio, and blood pressure), as well as with cholesterol and
metabolic markers. There was a modest inverse correlation
with loge hsCRP (r=0.25). Baseline total bilirubin levels
were higher by 25% in men compared with women. Levels
were lower by 13% in the combined group of current and
former smokers compared with noncurrent smokers
(Table 2).
Total Bilirubin Levels and Risk of Incident
Hypertension
During a median (interquartile) follow-up of 10.7 (5.5–11.6)
years, 1206 incident hypertension cases (incidence rate of
34.3 per 1000 person-years at risk; 95% conﬁdence interval
[CI], 32.4–36.3) were recorded. Total bilirubin was approx-
imately log-linearly associated with hypertension risk in
analyses adjusted for established hypertension risk factors
(smoking status, history of diabetes mellitus, SBP, total
cholesterol, body mass index, parental history of hyperten-
sion, alcohol consumption, and estimated glomerular ﬁltra-
tion rate; Figure 1). A linear shape was also suggested on
ﬁtting a fractional polynomial model (Figure S2). In age- and
sex-adjusted analysis, the hazard ratio for hypertension per
1-SD change in loge total bilirubin was 0.86 (95% CI, 0.81–
0.92; P<0.001), which was attenuated to 0.94 (95% CI,
0.88–0.99; P=0.035) after further adjusting for several risk
factors for hypertension. The results remained consistent on
further adjustment for urinary albumin excretion and home-
ostasis model assessment of insulin resistance 0.94 (95%
CI, 0.88–0.99; P=0.040). The association did not reach
formal signiﬁcance after additional adjustment for hsCRP
0.94 (95% CI, 0.88–1.00; P=0.067; Table 3). However, in an
age- and sex-only–adjusted analysis, the initial association
0.86 (95% CI, 0.81–0.92; P<0.001) was only minimally
attenuated after single additional adjustment for hsCRP 0.90
(95% CI, 0.85–0.96; P=0.001). In analyses that compared
the top versus bottom quartile of total bilirubin, the inverse
associations between total bilirubin and incident hyperten-
sion were maintained (Table 3). In sensitivity analyses, the
hazard ratios remained similar on exclusion of the ﬁrst
2 years of follow-up, people with diabetes mellitus at
baseline, people on cholesterol lowering medication, or
people with potential Gilbert’s syndrome (Table S2). The
association between total bilirubin and incident hypertension
was not statistically signiﬁcantly modiﬁed by several clini-
cally relevant characteristics (Figure 2). The association
between total bilirubin and hypertension risk remained
consistent similar when design-based Cox regression anal-
ysis was used (Table S3).
Evidence From Genome-Wide Association Studies
In the International Consortium of Blood Pressure, the
associations of rs6742078 with blood pressure were not
statistically signiﬁcant; 0.187 mm Hg per additional copy of
the T allele (SE, 0.103; P=0.06) for SBP and 0.122 (SE, 0.066;
P=0.07) for DBP. Similarly, in the BPExome consortium,
associations were nonstatistically signiﬁcant; P=0.24 for SBP,
P=0.85 for DBP, and P=0.97 for hypertension. These results
provide evidence against a strong causal role of long-term
elevated levels of bilirubin in decreasing blood pressure.
Discussion
Key Findings
In this population-based study comprising white men and
women without a history of hypertension and pre-existing
disease at baseline, we have shown that total bilirubin is
inversely associated with the future risk of hypertension in an
approximately log-linear fashion. The association was inde-
pendent of several established risk factors for hypertension
and other potential confounders. The association was
marginally signiﬁcant on further adjustment for hsCRP;
however, the association was only minimally attenuated after
single adjustment for hsCRP in an analysis that was initially
only adjusted for age and sex. The inverse association
between total bilirubin and incident hypertension was not
modiﬁed by several clinically relevant characteristics and
remained consistent in several sensitivity analyses. Further-
more, utilizing large-scale genetic data, the rs6742078 SNV
had small effects on blood pressure, but lacked statistical
signiﬁcance. The current results argue against a strong causal
role of circulating bilirubin in the etiology of blood pressure
reduction, but cannot rule out a weak causal effect.
Comparison With Previous Studies
A number of epidemiological studies have suggested an
inverse association between total bilirubin and hypertension
or blood pressure; but there were several limitations of these
previous reports and which included utilization of cross-
sectional designs, small sample sizes, or use of selected
populations.15,16,20,38 Chin et al, in their analysis of a cohort
of 1208 normotensive Korean men and women, showed
serum bilirubin to be associated with lower incidence of
hypertension.16 However, this analysis was somewhat limited
by the relatively low event rate in the exposed group, the
staggered follow-up evaluations, and the sampling frame,
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which was not representative of the general population. In an
elegant analysis of National Health and Nutrition Examination
Surveys 1999–2012, Wang and Bautista robustly demon-
strated that serum bilirubin was inversely associated with SBP
and hypertension14; however, the main limitation of this study
was its cross-sectional design, which precluded the ability to
assess the temporal relationship between bilirubin and risk of
hypertension and minimize reverse causation bias. To our
Table 2. Cross-Sectional Correlates of Total Bilirubin
Partial Correlation
r (95% CI)*
Percentage Difference
(95% CI) in Total Bilirubin
Levels Per 1 SD Higher
or Compared With
Reference Category of Correlate†
Total bilirubin, lmol/L  
Sex
Female  Ref
Male  25% (21, 28)k
Questionnaire
Age at survey, y 0.05 (0.08, 0.01)‡ 2% (3, 1)‡
History of diabetes mellitus
No  Ref
Yes  8% (23, 12)
Smoking status
Nonsmokers  Ref
Current and former smokers  13% (16, 11)k
Alcohol consumption
Nonconsumers  Ref
Current consumers  6% (3, 9)§
Parental history of hypertension
No  Ref
Yes  1% (4, 2)
Physical measurements
BMI, kg/m2 0.17 (0.20, 0.14)k 7% (8, 6)k
WHR 0.14 (0.17, 0.10)‡ 7% (9, 6)k
SBP, mm Hg 0.05 (0.08, 0.02)‡ 2% (4, 1)§
DBP, mm Hg 0.09 (0.12, 0.06) 4% (5, 3)k
Lipid, metabolic, inflammatory, and renal markers
Total cholesterol, mmol/L 0.15 (0.18, 0.12)k 7% (8, 5)k
Glucose, mmol/L 0.09 (0.12, 0.06)§ 4% (5, 3)k
Fasting insulin, units/mL 0.21 (0.24, 0.18)k 8% (9, 7)k
HOMA-IR 0.21 (0.24, 0.18)k 8% (10, 7)k
hsCRP, mg/L 0.25 (0.27, 0.22)k 10% (11, 9)k
eGFR, mL/min per 1.73 m2 0.01 (0.04, 0.02) 1% (2, 1)
UAE, mg/24 h 0.04 (0.07, 0.01) 1% (2, 1)
BMI indicates body mass index; DBP, diastolic blood pressure; eGFR, estimated glomerular ﬁltration rate (as calculated using the Chronic Kidney Disease Epidemiology Collaboration
combined creatinine-cystatin C equation); HDL-C, high-density lipoprotein cholesterol; HOMA-IR, homeostasis model assessment of insulin resistance; hsCRP, high-sensitivity C-reactive
protein; Ref, reference; SBP, systolic blood pressure; UAE, urinary albumin excretion; WHR, waist-to-hip ratio.
*Partial correlation coefﬁcients between loge total bilirubin and the row variables.
†Percentage change in total bilirubin levels per 1-SD increase in the row variable (or for categorical variables, the percentage difference in mean total bilirubin levels for the category vs the
reference) adjusted for age and sex.
Asterisks indicate the level of statistical signiﬁcance: ‡P<0.05; §P<0.01; kP<0.001.
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knowledge, our study is the ﬁrst to assess the long-term
prospective association between total bilirubin and risk of
hypertension in a general white population. We demonstrated
a modest effect of total bilirubin on hypertension risk, a
ﬁnding that was also demonstrated in the National Health and
Nutrition Examination Surveys 1999–2012 analysis. In a
recent study, which evaluated the association between
bilirubin and several cardiovascular risk factors, the research-
ers demonstrated a lack of an effect of bilirubin on blood
pressure in both observational and MR analyses.22 Whether
baseline circulating total bilirubin has an inverse association
with future hypertension risk may need to be conﬁrmed in
other large-scale, prospective cohort studies, given the limited
evidence.
Table 3. Association of Baseline Total Bilirubin Levels With Incident Hypertension
Total Bilirubin
Level, lmol/L Events/Total
Model 1 Model 2 Model 3 Model 4
HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value
Per 1-SD increase 1206/3989 0.86 (0.81–0.92) <0.001 0.94 (0.88–0.99) 0.035 0.94 (0.88–0.99) 0.040 0.94 (0.88–1.00) 0.067
Q1 (0.95–5) 367/1134 Ref Ref Ref
Q2 (6–7) 381/1184 0.92 (0.80–1.06) 0.267 1.00 (0.86–1.16) 0.978 0.99 (0.86–1.15) 0.924 1.00 (0.86–1.16) 0.992
Q3 (8–9) 243/826 0.83 (0.70–0.98) 0.026 0.97 (0.82–1.14) 0.700 0.97 (0.82–1.15) 0.736 0.98 (0.83–1.16) 0.834
Q4 (≥10) 215/845 0.68 (0.57–0.81) <0.001 0.82 (0.68–0.98) 0.033 0.82 (0.68–0.99) 0.035 0.83 (0.69–1.00) 0.055
Model 1: Age and sex. Model 2: Model 1 plus smoking status, history of diabetes mellitus, systolic blood pressure, total cholesterol, body mass index, parental history of hypertension,
alcohol consumption, and estimated glomerular ﬁltration rate (as calculated using the Chronic Kidney Disease Epidemiology Collaboration combined creatinine-cystatin C equation). Model
3: Model 2 plus loge urinary albumin excretion and loge homeostasis model assessment of insulin resistance. Model 4: Model 3 plus loge high-sensitivity C-reactive protein. CI indicates
conﬁdence interval; HR, hazard ratio; Q, quintile.
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Figure 1. Hazard ratios for incident hypertension, by baseline levels of total bilirubin using ﬂoating absolute risks. A, Hazard ratios were
adjusted for age and sex; (B) adjustment in A plus smoking status, history of diabetes mellitus, systolic blood pressure, total cholesterol, body
mass index, parental history of hypertension, alcohol consumption, and estimated glomerular ﬁltration rate (as calculated using the Chronic
Kidney Disease Epidemiology Collaboration combined creatinine-cystatin C equation). CI indicates conﬁdence interval.
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Potential Explanations for Findings
Bilirubin, iron, and carbon monoxide (CO) constitute the 3
metabolites of heme degradation by heme oxygenase (HO).
These degradation products of the HO reaction have been
suggested to regulate important functions in cells.39
Bilirubin has been suggested to contribute to reduced
CVD risk mainly through its antioxidant actions2,3 and anti-
inﬂammatory effects.4 Like CVD, oxidative stress mecha-
nisms are involved in the pathophysiology of hyperten-
sion.40,41 Vascular reactive oxygen species, which are
generated during oxidative reactions, are known to be
important contributors to the development of hyperten-
sion,42 because they cause impairment of mechanisms that
modulate arterial blood pressure.43,44 Increased production
of reactive oxygen species in the renal medulla is primarily
responsible for angiotensin-II–dependent hypertension.45
Given this, it has been postulated that the protective effect
of bilirubin on elevated blood pressure may be through its
potent antioxidant effects.46 It has been suggested that the
primary role of bilirubin in the whole process is its
inhibition of nicotinamide adenine dinucleotide phosphate
oxidase, which is the main enzyme responsible for the
generation of vascular reactive oxygen species.47,48 Bilirubin
Age at survey (years)
< 50
≥ 50
Sex
Males
Females
Smoking status
Non-smokers
Current and former smokers
Alcohol consumption
Non-alcohol consumers
Alcohol consumers
Parental history of hypertension
No
Yes
Fasting glucose (mmol/l)
< 4.7
≥ 4.7
Body mass index (kg/m2)
< 24.54
≥ 24.54
Systolic blood pressure (mmHg)
< 119
≥ 119
Total cholesterol (mmol/l)
< 5.40
≥ 5.40
Estimated GFR (ml/min/1.73 m2)
< 92.78
≥ 92.78
C-reactive protein (mg/l)
< 0.96
≥ 0.96
Gamma-glutamyltransferase (U/L)
< 21
≥ 21
UAE (mg/24 hours)
< 30
≥ 30
Subgroup
2,775
1,197
1,784
2,188
1,266
2,706
859
3,113
2,790
1,182
2,254
1,718
1,986
1,986
2,015
1,957
1,990
1,982
1,986
1,986
1,989
1,983
2,013
1,959
3,681
291
No. of participants
642
558
600
600
343
857
299
901
824
376
552
648
451
749
302
898
446
754
705
495
493
707
461
739
1,070
130
No. of hypertension 
cases
0.90 (0.83, 0.97)
1.00 (0.91, 1.09)
0.94 (0.87, 1.02)
0.93 (0.85, 1.02)
0.91 (0.82, 1.02)
0.95 (0.88, 1.02)
0.98 (0.87, 1.11)
0.92 (0.86, 0.99)
0.94 (0.87, 1.01)
0.93 (0.83, 1.03)
0.96 (0.88, 1.05)
0.92 (0.85, 1.00)
0.92 (0.84, 1.02)
0.93 (0.86, 1.00)
0.95 (0.84, 1.07)
0.95 (0.89, 1.02)
0.91 (0.83, 1.01)
0.94 (0.87, 1.02)
0.93 (0.86, 1.01)
0.94 (0.86, 1.03)
0.93 (0.85, 1.02)
0.95 (0.87, 1.03)
0.94 (0.86, 1.04)
0.93 (0.86, 1.00)
0.95 (0.89, 1.02)
0.80 (0.67, 0.96)
HR (95% CI)
.089
.814
.603
.394
.820
.449
.944
.995
.584
.922
.752
.817
.075
P-value*
1.5 .75 1.5
HR (95% CI) per 1SD higher loge total bilirubin levels
Figure 2. Hazard ratios for total bilirubin and hypertension risk by several participant level characteristics. Ratios were adjusted for age, sex,
smoking status, history of diabetes mellitus, systolic blood pressure, total cholesterol, body mass index, parental history of hypertension,
alcohol consumption, and estimated glomerular ﬁltration rate (GFR; as calculated using the Chronic Kidney Disease Epidemiology Collaboration
combined creatinine-cystatin C equation); CI indicates conﬁdence interval (bars); HR, hazard ratio; UAE, urine albumin excretion. *P value for
interaction; cutoffs used for fasting glucose, body mass index, systolic blood pressure, total cholesterol, estimated GFR, and C-reactive protein
are median values.
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also inhibits protein kinase C activity49 and scavenges the
superoxide anions in vascular cells, which inhibits the
pressor actions of angiotensin II.13 In addition to its
antioxidant effects, bilirubin exhibits anti-inﬂammatory
effects through its anticomplement actions.50 Given that
inﬂammation has been implicated in the development of
hypertension, circulating bilirubin might be involved in the
modulation of blood pressure through its anti-inﬂammatory
effects.51 Finally, low serum bilirubin levels have been
shown to be associated with impaired ﬂow-mediated
vasodilation,52 a measure of endothelial dysfunction; which
has been shown to precede the development of hyperten-
sion.53 There is also a possibility that the blood-pressure–
lowering effect of bilirubin could be partly attributed to CO,
mostly known as a toxic gas if the exposure is high.
Though the function of CO has not been clearly elucidated;
in low concentrations, CO has antiapoptotic properties as
well as vascular protective and anti-inﬂammatory proper-
ties,54,55 which may contribute to blood pressure regulation.
The effects of CO include vasodilation, inhibition of vascular
smooth muscle cells proliferation, and induction of angio-
genesis.56,57 Accumulating evidence suggests that the HO
pathway, through the production of CO and bilirubin, may
be responsible for regulating vascular function as well as
blood pressure.39 Findings from the current study do not
provide strong evidence for a causal association between
circulating total bilirubin and hypertension. This suggests
that the inverse associations demonstrated in the current
and previous observational studies may be driven by
biases such as unmeasured confounding and/or reverse
causation.
Implications of Findings
Irrespective of the weak protective effective of total bilirubin on
future hypertension risk and lack of evidence of a strong causal
role, its potential role in the prevention and control of
hypertension as well as CVD has been the subject of
considerable debate.14,18–20 Proven interventions that induce
increase in safe levels of circulating bilirubin leading to clinically
relevant decreases in blood pressure are currently unavailable.
Lifestyle interventions (such as smoking cessation, weight loss,
and physical activity)58,59 and pharmacological agents (HO-1
inducers such as statins, aspirin, resveratrol, and niacin and
drugs that inhibit hepatic uptake)60,61 may cause safe eleva-
tions in circulating levels of bilirubin, but there is limited
evidence on their potential effects on blood pressure. These
pharmacological agents cause mild-to-moderate elevations in
circulating levels of bilirubin and have been proposed as future
tools for CVD prevention and treatment.62 It has been
suggested that the HO-1 pathway may represent a novel
therapeutic target for the prevention of CVD.39 The
measurement of circulating total bilirubin involves a routinely
available blood test, which is simple, cheap, and well standard-
ized; therefore, it would be of immense clinical beneﬁt if bilirubin
is demonstrated to have a role in preventing hypertension as
well as CVD. However, further research is needed and caution is
required given that markedly elevated levels of bilirubin levels
may exert toxic effects4,63 and cause an increase in the risk of
CVD64,65 and mortality.66
Strengths and Limitations
The strengths of the current study include the large,
population-based cohort, which was representative of the
general population; exclusion of hypertensive individuals at
baseline as well as those with pre-existing diseases, such as
CVD, renal disease, or malignancy, which minimized any
possibilities of reverse-causation bias; comprehensive data on
lifestyle and biochemical factors, which allowed control for
potential confounders; comprehensive analysis, such as
evaluating the shape of the association and effect modiﬁca-
tion by clinically relevant characteristics; and robustness of
the ﬁndings in several sensitivity analyses. Furthermore, we
have utilized an MR approach using summarized large-scale
published data to assess the associations of a speciﬁc genetic
variant for circulating bilirubin with blood pressure. A number
of limitations should also be considered when interpreting
these results. First, because our data were observational,
residual confounding attributed to errors in risk marker
measurements and unmeasured confounders remains an
alternative explanation. Second, absence of repeat measure-
ments of total bilirubin precluded the ability to correct for
within-person variability in plasma total bilirubin levels and
this could have underestimated the associations, as a result
of regression dilution given the long-term follow-up of the
cohort.67,68 Circulating bilirubin has been shown to exhibit
high within-person variability,69 hence the associations
demonstrated may even be stronger. Larger-scale prospective
studies with repeat measurements of circulating total bilirubin
are needed to reliably assess the magnitude of the associ-
ations. Third, measurements of total bilirubin in the PREVEND
study involved prolonged plasma storage, which could have
contributed to the modest effect of total bilirubin on
hypertension risk. Fourth, we assessed bilirubin concentra-
tions in the fasting state, when the levels are highest. Because
we had no data on nonfasting bilirubin concentrations, we
were unable to investigate its concentrations in the nonfasting
state and how these concentrations affect hypertension. Fifth,
the current analysis involved principally white-European
participants, which hampers the generalization of our ﬁndings.
Finally, our MR approach was based on published publicly
available data, which precluded the ability to fully assess
instrumental variable assumptions. Given the unavailability of
DOI: 10.1161/JAHA.117.006503 Journal of the American Heart Association 9
Total Bilirubin and Incident Hypertension Kunutsor et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 by guest on M
arch 13, 2018
http://jaha.ahajournals.org/
D
ow
nloaded from
 
interventions that speciﬁcally inﬂuence levels of bilirubin
alone70 and can be safely administered to large numbers of
subjects for a prolonged period, causal inferences using
randomized trials of interventions that modify bilirubin levels
are not feasible in the short term. Further MR studies using
large-scale, individual-level data may help to establish or rule
out causality.
Conclusions
The weak and inverse association of circulating total bilirubin
with future hypertension risk may be driven by biases such as
unmeasured confounding and/or reverse causation. However,
given the limitations of the present study, further evaluation is
needed to rule out any causal association and assess any
potential relevance of circulating total bilirubin in the preven-
tion of hypertension.
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Table S1. STROBE 2007 Statement—Checklist of items that should be included in reports of cohort studies 
 
Section/Topic Item 
# 
Recommendation Reported on page # 
 Title and abstract 1 (a) Indicate the study’s design with a commonly used term in the title or the abstract Page 1 
(b) Provide in the abstract an informative and balanced summary of what was done and what was found Page 2 
Introduction  
Background/rationale 2 Explain the scientific background and rationale for the investigation being reported Page 3 
Objectives 3 State specific objectives, including any prespecified hypotheses Page 3-4 
Methods  
Study design 4 Present key elements of study design early in the paper Study population  
 
Setting 5 Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection Study population  
 
Participants 6 (a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up Study population  
 
(b) For matched studies, give matching criteria and number of exposed and unexposed Not applicable 
Variables 7 Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable Risk Factor Assessment 
 
Data sources/ 
measurement 
8*  For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of 
assessment methods if there is more than one group 
Risk Factor Assessment 
 
Bias 9 Describe any efforts to address potential sources of bias Statistical Methods 
Study size 10 Explain how the study size was arrived at Statistical Methods  
Quantitative variables 11 Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why Statistical Methods  
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Statistical methods 12 (a) Describe all statistical methods, including those used to control for confounding Statistical Methods  
(b) Describe any methods used to examine subgroups and interactions Statistical Analyses 
 
(c) Explain how missing data were addressed Not applicable 
(d) If applicable, explain how loss to follow-up was addressed Not applicable 
(e) Describe any sensitivity analyses Statistical Methods  
Results 
 
Participants 13* (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, 
included in the study, completing follow-up, and analysed 
Study population  
 
  (b) Give reasons for non-participation at each stage Study population  
  (c) Consider use of a flow diagram  
Descriptive data 14* (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders Results; Tables 1 and 2 
  (b) Indicate number of participants with missing data for each variable of interest  
  (c) Summarise follow-up time (eg, average and total amount) Results 
Outcome data 15* Report numbers of outcome events or summary measures over time Results 
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make 
clear which confounders were adjusted for and why they were included 
Results; Table 3 
  (b) Report category boundaries when continuous variables were categorized Results; Table 3 
  (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period  
Other analyses 17 Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses Results; Figure 2; 
Tables S2 and S3 
Discussion 
   
Key results 18 Summarise key results with reference to study objectives Discussion - Summary 
of main findings 
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Limitations    
Interpretation 20 Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, 
and other relevant evidence 
Discussion 
Generalisability 21 Discuss the generalisability (external validity) of the study results Discussion 
Other information 
   
Funding 22 Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present 
article is based 
Page 16 
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Table S2. Association of baseline total bilirubin levels with incident hypertension in several sensitivity analyses. 
 
 Events/ 
Total 
Model 1  Model 2  Model 3  Model 4  
  HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value 
Exclusion of first 2 years of 
follow-up 
1,112 / 3,895 0.86 (0.81 to 0.91) < 0.001 0.93 (0.87 to 0.99) 0.030 0.93 (0.87 to 
0.99) 
0.040 0.94 (0.88 to 1.00) 0.061 
Exclusion of people with 
diabetes at baseline 
1,196 / 3,970 0.87 (0.82 to 0.92) < 0.001 0.94 (0.88 to 0.99) 0.037 0.94 (0.88 to 
0.99) 
0.040 0.94 (0.88 to 1.00) 0.066 
Exclusion of people on 
cholesterol lowering 
medication 
1,163 / 3,892 0.86 (0.81 to 0.91) < 0.001 0.93 (0.87 to 0.99) 0.018 0.92 (0.87 to 
0.99) 
0.017 0.93 (0.87 to 0.99) 0.032 
Exclusion of people with 
potential Gilbert’s disease 
1,205 / 3,985 0.86 (0.81 to 0.92) < 0.001 0.93 (0.88 to 0.99) 0.032 0.94 (0.88 to 
0.99) 
0.037 0.94 (0.88 to 1.00) 0.063 
 
CI, confidence interval; HR, hazard ratio; Q, quartile; SD, standard deviation; HRs are estimated per 1 SD increase in loge total bilirubin 
Model 1: Age and sex 
Model 2: Model 1 plus smoking status, history of diabetes, systolic blood pressure, total cholesterol, body mass index, parental history of hypertension, alcohol consumption, 
and estimated glomerular filtration rate (as calculated using the Chronic Kidney Disease Epidemiology Collaboration combined creatinine-cystatin C equation) 
Model 3: Model 2 plus loge urinary albumin excretion and loge homeostasis model assessment of insulin resistance 
Model 4: Model 3 plus loge high-sensitivity C-reactive protein 
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Table S3. Association of baseline total bilirubin levels with incident hypertension using complex survey analyses. 
 
Serum total bilirubin 
level (µmol/l) 
Events/ 
Total 
Model 1  Model 2  Model 3  Model 4  
  HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value 
Per 1 SD increase 1,206 / 3,989 0.84 (0.79 to 
0.89) 
< 0.001 0.90 (0.84 to 
0.97) 
0.004 0.90 (0.84 to 0.97) 0.005 0.91 (0.84 to 0.97) 0.007 
Q1 (0.95-5) 367 / 1,134 ref  ref  ref  ref  
Q2 (6-7) 381 / 1,184 0.90 (0.78 to 
1.05) 
0.186 0.97 (0.82 to 
1.14) 
0.705 0.95 (0.81 to 1.13) 0.581 0.96 (0.81 to 1.13) 0.609 
Q3 (8-9) 243 / 826 0.82 (0.69 to 
0.97) 
0.018 0.94 (0.78 to 
1.12) 
0.479 0.94 (0.79 to 1.13) 0.522 0.95 (0.79 to 1.14) 0.558 
Q4 (≥ 10) 215 / 845 0.62 (0.52 to 
0.74) 
< 0.001 0.75 (0.62 to 
0.91) 
0.003 0.75 (0.61 to 0.91) 0.004 0.75 (0.62 to 0.92) 0.005 
 
CI, confidence interval; HR, hazard ratio; Q, quartile; SD, standard deviation 
Model 1: Age and sex 
Model 2: Model 1 plus smoking status, history of diabetes, systolic blood pressure, total cholesterol, body mass index, parental history of hypertension, alcohol consumption, 
and estimated glomerular filtration rate (as calculated using the Chronic Kidney Disease Epidemiology Collaboration combined creatinine-cystatin C equation) 
Model 3: Model 2 plus loge urinary albumin excretion and loge homeostasis model assessment of insulin resistance 
Model 4: Model 3 plus loge high-sensitivity C-reactive protein 
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Figure S1. Frequency distribution of plasma total bilirubin in the study sample. 
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Figure S2. Hazard ratios for incident hypertension using multivariate-adjusted fractional polynomials. 
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A, Hazard ratios were adjusted for age and sex; B, adjustment in A plus smoking status, history of diabetes, systolic 
blood pressure, total cholesterol, body mass index, parental history of hypertension, alcohol consumption, and 
estimated glomerular filtration rate (as calculated using the Chronic Kidney Disease Epidemiology Collaboration 
combined creatinine-cystatin C equation)  
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